Strumento inattivo

Altre lingue Neuropathix, Inc.

Azioni

NPTX

US64132Q1094

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

NEUROPATHIX, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	23/05/22
Neuropathix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	23/05/22
Neuropathix : OTC Certification - Neuropathix, Inc. - FYE 2021	25/04/22
Neuropathix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	15/04/22
NEUROPATHIX, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K)	15/04/22
Neuropathix, Inc. Auditor Raises 'Going Concern' Doubt	15/04/22
NEUROPATHIX, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)	25/03/22
Neuropathix, Inc. announced that it has received $0.15 million in funding	21/03/22
NEUROPATHIX, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	12/11/21
Neuropathix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	12/11/21
NEUROPATHIX, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	28/09/21
Neuropathix, Inc. Appoints Michael Ropacki to its Scientific Advisory Board	12/08/21
NEUROPATHIX : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	06/08/21
Neuropathix, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	06/08/21
Neuropathix : Neuropathix, Inc.	20/07/21
NEUROPATHIX : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	13/05/21
Neuropathix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	13/05/21
Neuropathix, Inc. Announces Publication of Validated Preclinical Studies on KLS-13019 in the British Journal of Pharmacology	06/05/21
NEUROPATHIX : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K)	30/03/21
Neuropathix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	30/03/21

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Neuropathix, Inc.

Azioni

NPTX

US64132Q1094

Altre lingue

Filtri